SIRT1 and metabolic dysfunction-associated steatotic liver disease: All in all, it was indicated that 4-AAQB ameliorated NAFLD by inhibiting the ER stress/NLRP3 inflammasome by activating the SIRT1-Nrf2 pathway, which needs to be further confirmed [71].